ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.902,42
1,63%
S&P 500
6.071,68
0,17%
Dow Jones
44.739,47
-0,30%
Euro vs US Dollar
1,03727
-0,27%
Bitcoin
96.544,41
-0,08%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
06/02/202515h53Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
06/02/202513h00Business WireAstraZeneca’s Full Year and Q4 2024 resultsNASDAQ:AZNAstraZeneca PLC
06/02/202511h45PR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
06/02/202506h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AZNAstraZeneca PLC
03/02/202519h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
03/02/202512h23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
03/02/202511h45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
30/01/202511h45PR Newswire (US)AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AZNAstraZeneca PLC
28/01/202500h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapiesNASDAQ:AZNAstraZeneca PLC
27/01/202511h45PR Newswire (US)Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
23/01/202520h33PR Newswire (Canada)AstraZeneca prévoit un investissement de 820 M$ CA (570 M$ US) au Canada pour consolider son statut grandissant de plaque tournante mondiale et faire progresser la réalisation d'essais cliniquesNASDAQ:AZNAstraZeneca PLC
23/01/202520h32PR Newswire (Canada)AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical deliveryNASDAQ:AZNAstraZeneca PLC
23/01/202511h45PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
23/01/202511h00PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
20/01/202511h45PR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
17/01/202523h35Business WireDATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
17/01/202513h00Business WireCALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphomaNASDAQ:AZNAstraZeneca PLC
16/01/202511h45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
13/01/202513h00Business WireDatopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
13/01/202511h45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
09/01/202511h45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
02/01/202519h50PR Newswire (US)AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZNNASDAQ:AZNAstraZeneca PLC
02/01/202516h42PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
30/12/202411h45PR Newswire (US)Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact The Gross Law FirmNASDAQ:AZNAstraZeneca PLC
18/12/202415h05PR Newswire (Canada)Alexion, la division des maladies rares d'AstraZeneca, et l'Alliance pharmaceutique pancanadienne (APP) parviennent à un accord au sujet de Koselugo (sélumétinib) pour le traitement des enfants atteints de neurofibromatose de type 1 (NF1) présentant deNASDAQ:AZNAstraZeneca PLC
18/12/202415h05PR Newswire (Canada)Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform nNASDAQ:AZNAstraZeneca PLC
11/12/202416h15Business WireLYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trialNASDAQ:AZNAstraZeneca PLC
09/12/202413h00Business WireDatopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
08/12/202417h00Business WireFixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trialNASDAQ:AZNAstraZeneca PLC
06/12/202413h00Business WireIMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancerNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

NASDAQ
TSLA
Tesla
COIN
XRPUSD
Ripple
AMEX
SPY
SPDR S&P 500
NYSE
KO
Coca Cola
TG
BAS
BASF
TG
432
Arbor Metals
NASDAQ
MSFT
Microsoft
DBI
DAX
DAX
TG
CBK
Commerzbank
FX
EURUSD
Euro vs US Dollar
NYSE
DIS
Walt Disney
TG
MBG
MercedesBenz
NYSE
MCD
McDonalds
CCOM
SILVER
SILVER
TG
BAYN
Bayer
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten